Cognitive & neurological research
Cerebrolysin: Research, Mechanism & Current Evidence
Peptide preparation derived from pig brain tissue, used clinically in some countries for stroke and dementia.
Also known as FPF-1070 · Cerebrolysin · Cerebrolysin®
What is Cerebrolysin?
Cerebrolysin is not a single molecule. It is a standardised mixture of low-molecular-weight peptides and amino acids produced from pig brain tissue, manufactured by EVER Pharma.
It is licensed in a number of countries in Europe and Asia for stroke, traumatic brain injury and dementia, but not in the UK, US or most of Western Europe.
What is Cerebrolysin researched for?
Ischaemic stroke recovery, which has the largest trial programme.
Traumatic brain injury and vascular dementia.
Alzheimer's disease, where results have been less consistent.
- Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
- Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
- Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.
- Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.
- Multiple trials including CAPTAIN series confirm GCS/GOS improvements.
- Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.
- Some studies show enhanced recovery; results vary significantly between trials.
- Early administration within 72 hours shows better outcomes than delayed treatment.
How does Cerebrolysin work?
The preparation is described as having neurotrophic activity — mimicking the effect of the body's own nerve growth factors on neuron survival and repair.
Because it is a mixture rather than a defined compound, the precise active constituents are not fully characterised, which is a genuine limitation of the mechanism story rather than a detail.
What does the research show?
Several randomised controlled trials and Cochrane reviews exist. The overall picture is mixed: some trials report functional improvement after stroke, while pooled analyses have generally found the evidence insufficient to support routine use.
Safety findings across trials have generally been unremarkable.
Limitations of the current evidence
Cochrane reviews have repeatedly concluded the evidence is not strong enough to recommend it for acute stroke, which is the indication with the most data.
Some published studies in this area have been retracted or criticised on methodological grounds, and a number of trials were conducted by parties with a commercial interest.
Batch-to-batch consistency is inherently harder to guarantee for a tissue-derived mixture than for a synthetic peptide.
References
Muresanu DF, Florian S, Hömberg V, et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
Phase IIIb/IV RCT: patients with GCS 7-12 received 50 mL Cerebrolysin daily for 10 days + two additional 10 mL cycles; confirmed beneficial effects on overall outcome after moderate-severe TBI.
PMID 31897941
Bornstein NM, Guekht A, Vester J, et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018
Meta-analysis of 1,879 stroke patients showed NIHSS superiority of Cerebrolysin (MW 0.60, P < 0.0001); NNT = 7.7 for clinically relevant early neurological improvement.
Controlled clinical trial · PMID 29248999
Wang Z, Shi L, Xu S, et al. · Drug design, development and therapy · 2017
Meta-analysis of 1,779 patients found no significant benefit on mRS response (RR 1.33, P=0.28) or Barthel Index; concluded routine use for long-term stroke rehabilitation not supported.
Controlled clinical trial · PMID 28458521
Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis
Jarosz K, Kojder K, Andrzejewska A, et al. · Brain sciences · 2023
10 studies of 8,749 TBI patients; GOS improvement was statistically significant (mean difference 0.422, P = 0.000); mortality and length of stay were not significantly affected.
Review or meta-analysis · PMID 36979317
Gauthier S, Proaño JV, Jia J, et al. · Dementia and geriatric cognitive disorders · 2015
6 RCTs in mild-to-moderate AD; Cerebrolysin significantly superior to placebo on ADAS-cog at 4 weeks (SMD -0.40, P=0.003) and CIBIC global clinical change at 4 weeks and 6 months.
Controlled clinical trial · PMID 25832905
This information is for educational and research purposes only. Consult a healthcare professional before use.
A comprehensive research database for peptides, therapies, and protocols. Information provided for educational purposes only.
© 2026 Peptide Database. For educational and research purposes only.
Common questions
Does Cerebrolysin actually work for stroke recovery or is the evidence mixed?
Evidence is mixed. Large meta-analysis of 1,879 stroke patients showed NIHSS (neurological function) superiority, but an independent analysis found no significant improvement in modified Rankin Scale (functional outcomes). Cerebrolysin appears to have early neurological benefits without clear long-term functional recovery advantage.
Is Cerebrolysin safe given some published studies have been retracted?
Yes, several Cerebrolysin studies were retracted due to research misconduct. However, well-conducted meta-analyses by independent researchers confirm safety and modest efficacy signals. Rely on meta-analyses and well-designed RCTs rather than individual studies, some of which have credibility issues.